Uncovering Phenotypic Expansion in AXIN2-Related Disorders
through Precision Animal Modeling

Nathalie M. Aceves-Ewing[1,*], Denise G. Lanza[1,*], Paul C. Marcogliese[2,3,*], Di Lu[1,4], Chih-Wei Hsu[5,6], Matthew Gonzalez[1], Audrey E. Christiansen[5], Tara L. Rasmussen[5], Alex J. Ho[7,8], Angelina Gaspero[1], John Seavitt[1], Mary E. Dickinson[1,5], Bo Yuan[1,9], Brian J. Shayota[10], Stephanie Pachter[11], Xiaolin Hu[12], Debra Lynn Day-Salvatore[13], Laura Mackay[14], Oguz Kanca[1,4], Michael F. Wangler[1,5], Lorraine Potocki[1,15], Jill A. Rosenfeld[1], Richard Alan Lewis[1], Hsiao-Tuan Chao[1,4,15,16,17,18,19], Brendan Lee[1,15], Sukyeong Lee[7,8], Undiagnosed Diseases Network[20], Baylor College of Medicine Center for Precision Medicine Models[21], Shinya Yamamoto[1,4,16], Hugo J. Bellen[1,4,16,*], Lindsay C. Burrage[1,15,*,#], Jason D. Heaney[1,22,*,#]

[1] Department of Molecular and Human Genetics, Baylor College of Medicine (BCM), Houston, TX, 77030, USA
[2] Department of Biochemistry and Medical Genetics, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, R3E 0J9, Canada
[3] Children's Hospital Research Institute of Manitoba (CHRIM), Winnipeg, MB, R3E 3P4, Canada
[4] Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital (TCH), Houston, TX, 77030, USA
[5] Department of Integrative Physiology, Baylor College of Medicine, Houston, TX, 77030, USA
[6] Optical Imaging and Vital Microscopy Core, Baylor College of Medicine, Houston, TX, 77030, USA
[7] Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, Houston, TX, 77030, USA
[8] Advanced Technology Core for Macromolecular X-ray Crystallography, Baylor College of Medicine, Houston, TX, 77030, USA
[9] Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, 77030, USA
[10] Division of Medical Genetics, Department of Pediatrics, University of Utah, Salt Lake City, UT, 84108, USA
[11] Atlantic Health System, Summit, NJ 07901, USA
[12] GeneDX, Gaithersburg MD, 20877, USA
[13] Department of Medical Genetics and Genomic Medicine, Saint Peter's University Hospital, New Brunswick, NJ, 08901, USA
[14] Department of Pediatrics, Division of Genetics and Metabolism, University of Texas Southwestern Medical Center, Dallas, TX, USA
[15] Texas Children's Hospital, Houston, TX, 77030, USA
[16] Department of Neuroscience, BCM, Houston, TX, 77030, USA
[17] The Cain Pediatric Neurology Research Foundation Laboratories, Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas, USA
[18] McNair Medical Institute, The Robert and Janice McNair Foundation, Houston, Texas, USA
[19] Division of Neurology and Developmental Neuroscience, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
[20] Member list in supplemental material
[21] Member list in supplemental material
[22] Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, 77030, USA
* These authors contributed equally
# Co-corresponding; emails: burrage@bcm.edu; heaney@bcm.edu

Keywords: ectodermal dysplasia, WNT/β-catenin signaling, oligodontia-colorectal cancer, AXIN2, tankyrase-binding domain

Abstract

Heterozygous pathogenic variants in *AXIN2* are associated with oligodontia-colorectal cancer

syndrome (ODCRCS), a disorder characterized by oligodontia, colorectal cancer, and in some

cases, sparse hair and eyebrows. We have identified four individuals with one of two *de novo*,

heterozygous variants (NM_004655.4:c.196G>A, p.(Glu66Lys) and c.199G>A, p.(Gly67Arg)) in

AXIN2 whose presentations expand the phenotype of AXIN2-related disorders. In addition to

ODCRCS features, these individuals have global developmental delay, microcephaly, and limb,

ophthalmologic, and renal abnormalities. Structural modeling of these variants suggests that

they disrupt AXIN2 binding to tankyrase, which regulates AXIN2 levels through PARsylation and

subsequent proteasomal degradation. To test whether these variants produce a phenotype *in*

vivo, we utilized an innovative prime editing N1 screen to phenotype heterozygous (p.E66K)

mouse embryos, which were perinatal lethal with short palate and skeletal abnormalities,

contrary to published viable *Axin2* null mouse models. Modeling of the p.E66K variant in the

Drosophila wing revealed gain-of-function activity compared to reference AXIN2. However, the

variant showed loss-of-function activity in the fly eye compared to reference AXIN2, suggesting

that the mechanism by which p.E66K affects AXIN2 function is cell context-dependent. Together,

our studies in humans, mice, and flies demonstrate that specific variants in the tankyrase-

binding domain of AXIN2 are pathogenic, leading to phenotypic expansion with context-

dependent effects on AXIN2 function and WNT signaling. Moreover, the modeling strategies

used to demonstrate variant pathogenicity may be beneficial for the resolution of other *de novo*

heterozygous variants of uncertain significance associated with congenital anomalies in

humans.

Introduction

The canonical WNT signaling pathway, also referred to as the β-catenin-dependent WNT pathway, is evolutionarily conserved and critical to embryonic development and adult homeostasis in nearly all animals. Since the WNT/β-catenin pathway is involved in many early developmental processes and in the maintenance of cell proliferation, diseases associated with dysregulated WNT signaling include a wide range of Mendelian and non-Mendelian phenotypes and several types of cancer. Some of the known disorders associated with aberrant WNT signaling include tooth agenesis[1-4], neurodegenerative disorders[5-7], and renal disease[8]. Cancers associated with members of the WNT signaling pathway include breast cancer[9-11], hepatocellular carcinoma[11-13], and colorectal cancer[1-3,11,13-17].

The inhibition and activation of the canonical WNT/β-catenin pathway involves multiple extracellular, membrane-bound, cytoplasmic, and nuclear proteins[18-22]. In the absence of WNT ligand binding to the receptor complex consisting of FZD and LRP5/6, β-catenin is constitutively phosphorylated by the destruction complex (composed of APC, CK1, GSK3β, and AXIN1 or AXIN2), leading to its ubiquitination and proteasomal degradation[21,23-28]. However, upon WNT binding, the activity of the destruction complex is inhibited and accumulated β-catenin translocates to the nucleus, where it associates with TCF/LEF transcription factors to activate the expression of genes involved in cell fate determination, cell proliferation, and other key cellular processes[14,26,27]. Critically, in some cell contexts AXIN2 can also positively regulate WNT signaling by binding to and maintaining the phosphorylation of the LRP5/6 receptors after WNT activation of its receptor complex[29-32].

Somatic variants in *AXIN2* have been associated with somatic colorectal cancer (MIM #114500)

whereas germline variants in *AXIN2* have been associated with oligodontia-colorectal cancer

syndrome (ODCRCS, MIM #608615)[1-4,9,10,15,16,33]. ODCRCS most commonly includes

phenotypes such as oligodontia, colon polyps, colorectal cancer, and sparse hair and

eyebrows[1-4,9,10,15,16,33,34]. To date, most published pathogenic variants in *AXIN2* cluster towards

the C-terminus of the protein as well as a few variants in the Regulator of G protein signaling

(RGS), GSK3β-binding, and β-catenin-binding domains[1-4,9,15,16]. However, to date, no

pathogenic variants have been identified in the tankyrase (TNKS)-binding domain[1-4,15,16,35-37].

This domain is necessary for TNKS binding, which leads to the poly-ADP-ribosylatation

(PARsylation), ubiquitination, and proteasomal degradation of AXIN2[35,37].

In this study, we report three individuals with ectodermal dysplasia, musculoskeletal anomalies,

genitourinary abnormalities, and a *de novo* heterozygous variant in the TNKS-binding domain

(p.Glu66Lys, referred to as E66K) of AXIN2. As pathogenic variants in this domain have not

been previously reported and as the phenotype associated with these variants was

hypothesized to be lethal in mice, we combined structural and fly modeling with innovative

mouse modeling strategies to demonstrate the pathogenicity of the p.E66K variant. In addition,

we used amino acid conservation and population databases to identify a neighboring variant

(p.Gly67Arg, referred to as G67R) that causes an overlapping human phenotype. Overall, we

demonstrate that variants impacting key residues in the TNKS-binding domain of AXIN2

represent a phenotypic expansion and novel ectodermal dysplasia associated with congenital

anomalies.

Materials and Methods

Clinical Study. Participant 1 and both parents were enrolled in the Baylor College of Medicine

(BCM) site for the Undiagnosed Diseases Network (UDN). This study was approved by the

Institutional Review Board (IRB) at both the National Institutes of Health and BCM. The family

provided written informed consent prior to the initiation of any research procedures. Additional

cases (participants 2, 3, and 4) were identified through a search of ClinVar[38] for variants at the

same or nearby positions and communications with the submitters of these variants (GeneDx

and Invitae). Participants 2, 3, and 4 and their families also provided written informed consent

prior to the initiation of research procedures under an IRB-approved protocol at BCM. *As per*

medRxiv policy, the case histories for the participants and their images have been removed. To

obtain more detailed information, please contact the authors.

Exome and Genome Sequencing. For participant 1, clinical trio exome sequencing was

performed at Baylor Genetics as previously described[39] and transferred to the BCM UDN site for

research re-analysis. Trio genome sequencing was performed through the UDN Sequencing

Core at Baylor Genetics as previously described[40], and research reanalysis was performed at

the BCM UDN site. The research exome and genome re-analyses prioritized rare, *de novo* and

biallelic variants that had an allele frequency of < 1% in gnomAD v4.0.0[41] and in the BCM UDN

internal sequencing database (> 1200 samples). Codified Genomics was used for variant

filtering and prioritization. Participant 2's variant was detected on an Invitae Hereditary

Colorectal Cancer panel as part of an evaluation for colon polyps. This next generation

sequencing panel included 20 genes associated with predisposition to colorectal cancer. Sanger

sequencing was performed using DNA extracted from parental buccal samples at Baylor

Genetics Laboratory to confirm that the *AXIN2* variant identified in participant 2 is *de novo*.

Participants 3 and 4 had clinical trio exome sequencing performed through GeneDx. For CADD

Scores, CADD GRCh37-v1.7 was used.

Conservation alignments. The conservation alignments were made using default parameters

in Clustal Omega (CLUSTAL O(1.2.4) multiple sequence alignment)[42-44] with *Homo sapiens*

AXIN2 (Q9Y2T1) as the reference sequence aligned with *Mus musculus* AXIN2 (O88566), and

Homo sapiens (O15169) and *Mus musculus* (O35625) AXIN1. Amino acid sequences were

acquired from UniProt[45]. A similar alignment was performed using *Homo sapiens* AXIN2

(Q9Y2T1) as the reference sequence aligned with fly (*Drosophila melanogaster*) AXN (Q9V407)

and AXIN2 amino acid sequences from the following organisms: *Mus musculus* (O88566),

Rattus norvegicus (O70240), *Pan troglodytes* (K7CHS6), *Gorilla gorilla gorilla* (G3QN00),

Macaca mulatta (A0A5F8AE66), *Pongo abelii* (H2NUH3), *Papio anubis* (A0A096NTX5),

Chlorocebus sabaeus (A0A0D9QVR2), *Otolemur garnettii* (H0WYQ7), *Microcebus murinus*

(A0A8B7F524), *Ictidomys tridecemlineatus* (I3N719), *Canis lupus familiaris* (A0A8C0YRK8),

Felis catus (M3XAL0), *Mustela putorius furo* (M3YT87), *Ailuropoda melanoleuca* (G1LZK8),

Equus caballus (F6SK96), *Pteropus vampyrus* (A0A6P6CVR3), *Bos taurus* (G3X7P3), *Sus*

scrofa (A0A287BFQ6), *Tursiops truncates* (A0A6J3QL77), *Sarcophilus harrisii* (G3VT89),

Monodelphis domestica (F6TVK6), *Anolis carolinensis* (H9G5B4), *Pelodiscus sinensis*

(K7G9P5), *Gallus gallus* (A0A1D5PPH8), *Latimeria chalumnae* (H3BCV4), *Ficedula albicollis*

(U3JIC1), *Danio rerio* (P57095), *Oreochromis niloticus* (I3J624), *Xiphophorus maculatus*

(A0A3B5QRG9), *Oryzias latipes* (H2L981), *Tetraodon nigroviridis* (H3C937), *Gasterosteus*

aculeatus (G3Q3K5), *Xenopus tropicalis* (A0A803JRP4), *Astyanax mexicanus* (A0A3B1KDC5),

and *Takifugu rubripes* (H2SP31).

Structural modeling. The side chains of the mutated E66K and G67R residues in the TNKS

binding motif 2 (TBM2) of AXIN2 were modeled based on the crystal structure of the TNKS

ankyrin-repeat clusters 2-3 (ARC2-3) and AXIN1 complex (PDB ID: 3UTM) as a template[37]. For

each variant, a rotamer conformation was selected for the mutated residue to model the side

chain, followed by minor adjustments of the *chi* angles. Structural modelling was performed using

Coot[46].

Mouse colony management. All mice were housed in microisolator cages in ventilated racks

within the ABBR animal facility at BCM. The rooms were temperature controlled and humidity

controlled with a 6:00 AM to 8:00 PM light:dark cycle. The mice were given *ad libitum* access to

food (Lab Diet 5V5R) and autoclaved drinking water for the duration of the study. All studies

were approved by the BCM Institutional Animal Care and Use Committee.

Axin2 **p.E66K founder embryo screen.** To generate founder embryos harboring a knock-in

(KI) of the p.E66K (GAG>AAG) point mutation, as well as a p.G67 (GGG>GGC) synonymous

mutation, two different design strategies were implemented, each using a single guide RNA

(sgRNA) with a complementary single-stranded oligodeoxynucleotide (ssODN) repair donor for

CRISPR/Cas9-initiated homology-directed repair (**Figure S1**). Inclusion of the synonymous

mutation in the ssODN sequence alters the sgRNA target sequence, thus reducing guide affinity

and suppressing secondary CRISPR genome editing events after homology-directed repair. The

sgRNAs were selected by the BCM Genetically Engineered Rodent Model (BCM GERM) Core

using the Wellcome Sanger Institute Genome Editing (WGE) website[47]. Complementary to the

strand of the target site, corresponding ssODNs were designed with asymmetric homology arms

flanking the p.E66K mutation relative to the predicted cut site of the gRNA. Sequences and

genomic coordinates can be found in **Table S1**. The sgRNAs were synthesized by Synthego

and custom ssODNs (Ultramers) were produced by Integrated DNA Technologies (Coralville,

IA). The BCM GERM Core electroporated a mixture consisting of precomplexed sgRNA (6.6

µM) and Cas9 Protein (6 µM, PNA Bio), ssDNA mRNA (100 pmol) in a final volume of 10 µL

1xTE (RNAse-free) into at least 60 pronuclear stage C57BL/6J (Jackson Lab Strain #:000664;

RRID:IMSR_JAX:000664) zygotes as previously described[48]. Embryos were transferred to

pseudopregnant females the same day as electroporation and allowed to gestate for 18 days

prior to sacrifice of the recipient dam and collection of embryos for subsequent genotyping and

imaging.

***Axin2^{E66K/+}* constitutive knock-in mouse model.** To generate a constitutive knock-in (KI)

mouse model with the p.E66K (GAG>AAG) point mutation as well as a p.G67 (GGA>GGG)

synonymous mutation, RNA-guided nuclease prime editing was utilized (**Figure S2A)**. A prime

editing guide RNA (pegRNA) and a complementary sgRNA to facilitate DNA nicking were

selected by the BCM GERM Core using Peg Finder[49]. Again, the synonymous mutation was

included to suppress secondary genome editing events. Target sequences, genomic

coordinates, and guide sequences can be found in **Table S2 and S3**. The pegRNA was

purchased as a custom gRNA from Integrated DNA Technologies (Coralville, IA) and the nicking

gRNAs as synthesized sgRNAs from Synthego (Redwood City, CA). Prime editor (PE2) mRNA

was generated from linearized plasmid DNA (pCMV-PE2, addgene.org/132775/) using the

mMESSAGE mMACHINE T7 ULTRA Transcription Kit (ThermoFisher, AM1345). The BCM

GERM Core microinjected a mixture consisting of pegRNA (75ng/µL), sgRNA (75ng/µL), and

PE2 mRNA (150ng/µL) in a final volume of 50 µL 1xTE (RNAse-free) into the cytoplasm of

C57BL/6J (Jackson Lab Strain #:000664; RRID:IMSR_JAX:000664) pronuclear stage zygotes

as previously described[50]. DNA was isolated from ear punches and PCR was performed with

AmpliTaq Gold 360 Master Mix (Applied Biosystems, 4398881) using primers Axin2 E2 F (5'

TCCAGAGAGGAGGCTCACAT) and Axin2 E2 R (5' AAACATGACCGAGCCGATCT). PCR

products were Sanger sequenced and Synthego ICE analysis identified a founder male with

approximately 20% mosaicism for an allele harboring the p.E66K point mutation and p.G67

synonymous mutation, as well as a p.S70 (TCG>TCC) synonymous mutation (**Figure S2B)**.

This founder was used for breeding and subsequently sperm cryopreservation using the CARD

method[51,52]. The allele is registered at Mouse Genome Informatics (MGI) as *Axin2*[em1Bay]

(MGI:7768058).

Embryo phenotyping. For the p.E66K embryo founder screen, embryos were collected at

embryonic day (E)18.5, fixed in 4% paraformaldehyde (PFA), and stored at 4°C until they could

be processed for µCT imaging, as previously described[53]. To generate N1 embryos harboring a

Axin2[E66K/+] constitutive knock-in allele, timed matings between the *Axin2*[E66K/+] mosaic male

founder and wild-type C57BL/6J females or *in vitro* fertilization with mosaic male sperm and

wild-type C57BL/6J oocytes were used as previously described[52,54,55]. Timed matings were set

up between male and female mice during the afternoon. If a vaginal plug was confirmed the

next morning, female and male mice were separated, and embryos were stated to be at E0.5.

Embryos were analyzed upon dissection at E18.5 with light microscopy. For µCT imaging, E18.5

embryos were fixed and processed as described for the founder screen. Embryos were scanned

with a Bruker SkyScan 1272 µCT Scanner, and images were analyzed with Slicer (v5.2.2).

Annotation of phenotypes was performed blinded to genotypes.

Embryo genotyping. DNA was extracted from yolk sacs for PCR-based genotyping and

Sanger sequencing. PCR was performed with AmpliTaq Gold 360 Master Mix using primers

Axin2 E2 F (5' TCCAGAGAGGAGGCTCACAT) and Axin2 E2 R (5'

AAACATGACCGAGCCGATCT). For the founder embryo screen, PCR products were Sanger

sequenced, and Synthego Inference of CRISPR Edits (ICE) analysis was used to determine

wild-type, insertion/deletion (non-homologous end joining), and variant (homology-directed

repair) allele contribution in each embryo. For N1 embryos derived from the mosaic $Axin2^{E66K/+}$

constitutive knock-in founder male, the same primers were used to generate PCR products,

which were subsequently digested with StyI High-Fidelity enzyme (NEB, R3500S). The

expected size for the wild-type product is 653 bp; StyI cleaves at the p.E66K sequence in the

$Axin2^{E66K}$ allele, resulting in 335 bp and 318 bp products (**Figure S2A&C**). Transmission of the

$Axin2^{E66K/+}$ constitutive knock-in allele from the mosaic founder to N1 embryos was also

confirmed via Sanger sequencing (**Figure S2B**).

Generation of AXIN2 transgenic flies. *UAS-AXIN2* reference and variant transgenic flies were

generated as previously described[56]. Specifically, the Gateway compatible *AXIN2*

(NM_004655.4) open-reading frame (ORF) in the DONR221 vector was shuttled to the pGW-

HA.attb[57] UAS destination vector by LR clonase II (Invitrogen) by manufacturer protocol. The

ORF harbors an endogenous stop codon, thus this closed clone will not be tagged with HA.

Variants were generated via site-directed mutagenesis with the Q5 mutagenesis kit (NEB)

followed by verification of the ORF by Sanger sequencing. Primers used for site-directed

mutagenesis for the *AXIN2* p.E66K, R656X, and W663X variants are listed in **Table S4**. Final

UAS constructs were microinjected into embryos containing the VK37 (PBac{y[+]-

attP}VK00037) genomic docking site and integrated by φC31 mediated transgenesis[58].

Generation of *AxnTG4* mutant flies. The Axn^{TG4} ($Axn^{CR70218-TG4.2}$; BL_ 93803 – BDSC) allele

was generated in a previous study as part of the large-scale gene disruption project[59]. Briefly,

we generated homology donor intermediates to target an intron separating two exons in the

coding region of *Axn*. Construct with homology arms (200 bases upstream and downstream of

the target site) and *Axn*-specific sgRNA that targets the site

(TCATCGAGTCAGTGGTGTAGAGG) was commercially synthesized in pUC57_Kan_gw_OK2

vector by Genewiz/Azenta. The sequence comprising a cassette that includes attP-FRT-splice

acceptor-T2A-GAL4-poly(A)-3×P3EGFP-poly(A)-FRT-attP was transferred from the pM37 vector

to the intermediary vector designed for homology, thereby generating a new homology donor

vector. The construct was injected at 250 ng/µl final concentration into 664 embryos from the

line: y^1w^*; *attP40(y+){nos-Cas9(v+)}; iso50.* Eclosed flies were crossed with y^1 w^* flies, and the

3×P3–EGFP-positive progeny were selected based on GFP expression in the adult eyes.

Protein Quantification. To determine human AXIN2 protein level upon overexpression in flies,

AXIN2 reference and variants were expressed pan-neuronally with *elav-GAL4*. Five fly heads

from each genotype were homogenized in a cell lysis buffer (RIPA buffer, 1X liquid protease

inhibitor (Gen DEPOT)) with an electric Dounce on ice. Next, Laemmli buffer and 5% β-

mercaptoethanol (BME) was added to each tube and lysed heads were incubated on ice for 10

minutes and boiled for five minutes at 95°C. Samples were centrifuged at 14,000 RPM for five

minutes at 4°C. The supernatant was loaded into 4-20% gradient gels (Mini-PROTEAN®

TGX™), separated by SDS-PAGE, and transferred to nitrocellulose membranes (Bio-Rad). The

following primary antibodies were used in this study: anti-Actin (mouse monoclonal: C4;

1:20,000) (EMD Millipore), anti-AXIN2 (rabbit monoclonal: 76G6; #2151; 1:1000) (Cell

Signaling). Corresponding HRP-conjugated secondaries were used at 1:10,000 dilution.

Immunostaining and imaging. The methods for preparing and visualizing *Drosophila* wing

discs were performed as previously reported[60]. To summarize, wing discs from third-instar

larvae at the wandering stage were dissected and preserved in 4% PFA. These samples were

subsequently immunostained with the following antibodies: mouse anti-Wingless at a dilution of

1:50 (Developmental Studies Hybridoma Bank [DSHB], clone 4D4), mouse anti-Cut at the same

dilution (DSHB, clone 2B10), and guinea pig anti-Senseless at a dilution of 1:100[61]. For the

mounting phase, Vectashield (Vector Labs, H-1000-10) was employed. The wing discs were

examined using a Zeiss LSM 880 laser confocal microscope. For the post-scanning image

enhancement, ZEN software from Zeiss and Imaris software from Oxford Instruments were

utilized.

Adult wing and eye preparation and imaging. Adult *Drosophila* wings were dissected and

mounted as previously described[60]. Briefly, wings from adult flies were excised and preserved in

70% ethanol before being arranged in a solution made from a mixture of CMCP-10 mounting

medium (sourced from Masters in Wood Dale, IL) and lactic acid in a ratio of 3 to 1. For eyes,

whole flies of appropriate genotypes were frozen at -20ºC for 24 hours before imaging. The

images for adult wings and eyes were captured using a Leica MZ16 stereomicroscope that was

outfitted with an Optronics MicroFire camera and operated using Image-Pro Plus software

version 7.0.

Statistical Analyses. A two-sided Fisher's exact test to determine if there was a significant

difference between genotype distribution across E18.5 and postnatal timepoints for the

Axin2$^{E66K/+}$ embryos and *Axin2*$^{+/+}$ littermates was done using GraphPad Prism (version 10.3.1

318 (509)). For *Drosophila* studies and quantification, ANOVA was followed by Tukey's post hoc test

319 using GraphPad Prism.

321 **Results**

322 ***De novo* heterozygous variants clustered in the TNKS-binding domain of AXIN2 cause**

323 **multiple congenital anomalies.** A cohort consisting of three individuals with the same

324 heterozygous *de novo* variant in *AXIN2* (NM_004655.4:c.196G>A, p.E66K) and overlapping

325 phenotype consisting of features of an ectodermal dysplasia as well as skeletal and

326 genitourinary anomalies was identified through the UDN and ClinVar. This variant was not

327 present in gnomAD(v4.0.0)[41] or in the BCM clinical site internal sequencing database. The

328 CADD score is 27.2[62], Revel score is 0.549[63], and AlphaMissense score is 0.765[64]. The glutamic

329 acid at this position is in the TNKS-binding domain of AXIN2[65] and is conserved in vertebrates

330 including mice and in zebrafish but not in *Drosophila melanogaster* (**Figure 1A and Figure**

331 **S3A**). This variant has been reported in the Catalogue of Somatic Mutations in Cancer

332 (COSMIC, v100) one time in a large intestinal adenocarcinoma from a 64-year-old male[66].

334 Based on structural modeling data of AXIN1 and tankyrase interactions[37], the proline at position

335 65 and the glycine at position 67 in AXIN2 are critical for the interaction between AXIN2 and

336 tankyrase[37]. Given that there is an absence of missense variation at these positions in

337 gnomAD(v4.0.0) (**Figure 1B, Figure S3B**) in conjunction with the conservation data, we

338 hypothesized that variants impacting positions 65 and 67 might cause phenotypes similar to

339 those with variants at position 66. Thus, we searched ClinVar for missense variation impacting

340 these neighboring amino acids. This search identified participant 4 with a similar phenotype who

341 has a *de novo* heterozygous variant at position 67 (NM_004655.4:c.199G>A, p.G67R). The

CADD score of the p.G67R variant is 27.4, REVEL score is 0.494, and AlphaMissense score is

0.971. This glycine is conserved in vertebrates including mice and zebrafish but not in

Drosophila melanogaster. This variant was also observed as a confirmed somatic heterozygous

variant in a large intestinal adenocarcinoma sample from a female of unknown age and a diffuse

adenocarcinoma of the stomach from a 38-year-old female in the COSMIC database(v100).

The phenotype observed in the four individuals with *de novo* heterozygous variants impacting

the glutamic acid at position 66 or the glycine at position 67 of AXIN2 is complex and variable.

Common phenotypes include digit and limb anomalies (4/4), global developmental delay (3/4),

microcephaly (3/4), ophthalmologic complications (3/4), genitourinary anomalies (3/4), unique

facial features (3/4), and palate abnormalities (2/4). Features suggestive of an ectodermal

dysplasia such as oligodontia (3/4), sparse hair (3/4), sparse eyebrows and eyelashes (3/4),

and nail abnormalities (2/4) are common. These findings together with sagittal craniosynostosis

suggested a diagnosis of cranioectodermal dysplasia in participant 3. Although three of the four

patients are children with complex phenotypes identified by exome or genome sequencing, one

individual is an adult whose variant in *AXIN2* was identified on a colorectal cancer panel. This

adult has a milder, but overlapping phenotype which includes digit abnormalities, skeletal

abnormalities, and history of vesicoureteral reflux in addition to a diagnosis of colon cancer with

>25 colon polyps. Detailed case reports are provided in supplemental material.

Structural modeling. Since no atomic structure is available for the TNKS/AXIN2 complex, we

attempted structure prediction of this complex *in silico* using AlphaFold2-multimer[67] initially, and

later using AlphaFold3[68]. TNKS proteins contain an ankyrin-repeat domain that consists of a

series of ankyrin-repeat clusters (ARCs)[37]. In the top five prediction results from AlphaFold2-

multimer, the first TNKS binding motif (TBM1) in AXIN2 binds the ankyrin-repeat domain ARC4 in

all five predicted structures, while the second binding motif (TBM2) binds to ARC5 in one predicted

structure. However, all five top predictions from AlphaFold3 shows only TBM2 binding to ARC5.

Pairwise comparison of the Alphafold predicted structure and the known crystal structure of the

ARC domain of TNKS with bound peptide (PDB IDs: 3UTM and 3TWW) shows that the peptide

binding interactions are very similar, with the peptides interacting on the same surface of ARC.

Currently, it is unclear which ARC of TNKS is the binding partner for each TBM. However, based

on results from the pulldown assay and sequence conservation of critical residues in ARC

implicated in TBM binding[37], it is likely to be one of ARC2, ARC4, or ARC5.

The amino acid residues impacted by our variants are located in TBM2. Due to the ambiguity

regarding which ARC is responsible for TBM2 binding and the relatively low confidence in the

AlphaFold prediction of complex formation partners, we used the known crystal structure of the

TNKS/AXIN1 complex[37], in which each ARC2 of TNKS binds TBM1 and TBM2 of AXIN1,

respectively, as a template for our *in silico* modeling of the variant structure. The arginine side

chain of the mutated Gly67 was modeled using Coot. However, every rotamer conformation of

the arginine clashes with surrounding TNKS residues in the complex, as there is no space to

accommodate the bulky side chain (**Figure 2C**). As previously suggested by Morrone et al., the

glycine-selection gate of TNKS is crucial for binding[37]. Consequently, the large side chain of the

p.G67R variant of AXIN2 would prevent AXIN2 from binding.

Figure 2D shows the Glu66 side chain forming a hydrogen bond with the Ser363 side chain and

water-mediated hydrogen bonds with the main chain N-H of K362 and S363, which participate

in an extensive hydrogen bond network. The same hydrogen bond network, including water

mediated hydrogen bond interactions, was also observed in the crystal structure of ARC4 of

TNKS bound to a chimeric substrate peptide (PDB ID: 3TWW)[69]. These interactions would

become less favorable when the glutamic acid is mutated to lysine due to its positive charge.

The p.E66K side chain mutation model was generated using Coot, with a rotamer conformation

that best maintained the hydrogen bond interactions. Currently, none of the versions of

AlphaFold can predict water mediated interactions; therefore, relevant crystal structures were

used as templates to analyze the mutant structure [37,69].

Congenital anomalies in a p.E66K founder mouse embryo screen. We next used

CRISPR/Cas9 genome editing in mice to confirm the pathogenicity and associated phenotypes

of the p.E66K variant. Because we anticipated that the phenotypes associated with

heterozygosity for p.E66K in humans would lead to postnatal lethality in mice, we employed a

founder embryo screen (**Figure 3A**). CRISPR/Cas9-mediated HDR was used to generate

embryos harboring an allele with the p.E66K variant and a neighboring synonymous variant

(see Materials and Methods; **Figure S1**). At E18.5, embryos (n=37) were collected and each

screened via Sanger sequencing and Synthego ICE analysis for the contribution of wild-type,

indel, and p.E66K knock-in alleles (**Table S5**). Of the 37 embryos screened, 5 were wild-type

and 26 harbored undesired indel mutations with or without the p.E66K knock-in allele. The

remaining 6 embryos harbored only the p.E66K knock-in allele; however, only 2 of the 6 had

knock-in allele contribution at or above 50% (96% and 53% knock-in allele contribution; sense

and antisense ssODN targeting, respectively). Because low mosaicism for the knock-in allele

may not be sufficient to produce phenotypes, µCT imaging was used to phenotype only these 2

knock-in embryos as well as a wild-type control sibling. Both p.E66K knock-in embryos

displayed kinked tail and shortened soft palate abnormalities not observed in the wild-type

control **(Figure 3B-D)**.

Confirmation of congenital anomalies using a p.E66K N1 mouse embryo screen. Although CRISPR founder screens bypass the need to generate a mouse line for phenotyping, mosaicism for the desired variant knock-in (HDR) allele, undesired indel (NHEJ) alleles, or both, in founders can confound detection of genotype-phenotype relationships[70]. Thus, we sought a mid-throughput approach to generate p.E66K heterozygous embryos for screening. We hypothesized that a CRISPR founder animal with low mosaicism for the p.E66K allele may survive to breeding age. From such an animal, N1 embryos heterozygous for the p.E66K allele could be consistently generated, and genotype-phenotype associations could be more easily established. To produce such a founder, we turned to prime editing, which has been shown to be inefficient when editing in the mouse germline[71-74].

Using prime editing, we produced a viable male founder that was 20% mosaic for an allele harboring the p.E66K variant and two neighboring synonymous variants ($Axin2^{E66K}$) (see Materials and Methods; **Figure S2**). Matings using the male founder produced six litters with a total of 30 liveborn N1 offspring, which were genotyped at 2-3 weeks of age. Interestingly, no heterozygous $Axin2^{E66K/+}$ offspring were identified (**Figure 4B**). Due to these results, we hypothesized that there was either no germline transmission of the p.E66K variant or the variant was associated with pre-weaning lethality. Therefore, we performed *in vitro* fertilization with founder sperm to determine if $Axin2^{E66K/+}$ N1 embryos were present and viable just prior to birth (E18.5). Of 29 viable N1 embryos collected at E18.5, 14 (48%) were heterozygous for the p.E66K variant allele. A Fisher's exact test comparing genotypes detected at E18.5 and weaning age showed a significant difference (p<0.0001) (**Figure 4B**). External examination of the 14 $Axin2^{E66K/+}$ E18.5 embryos revealed kinked tail abnormalities (N=5; 36%), missing digit (N=1; 7%), and edema or hydrocephalus (N=2; 14%). These phenotypes were not observed in 9 $Axin2^{+/+}$ littermate controls. We performed μCT imaging on the $Axin2^{+/+}$ and $Axin2^{E66K/+}$ embryos,

which confirmed the observed external phenotypes (**Figure 4C&D; Figure S4**). Critically,

μCT imaging also revealed a shortened soft palate phenotype in all *Axin2*$^{E66K/+}$ embryos, which

was not observed in any *Axin2*$^{+/+}$ controls (**Figure 4D; Figure S5**). Together, the results from our

N1 embryo screen demonstrate that heterozygosity for *Axin2*^{E66K} causes lethality between birth

and weaning and embryonic phenotypes like those observed in the founder screen and in the

participants. Moreover, these results suggest that lethality may be secondary to the shortened

palate observed in *Axin2*$^{E66K/+}$ embryos.

The p.E66K variant allele functions differently than *AXIN2* reference and pathogenic

ODCRCS variant alleles in *Drosophila*. Although the Glu66 residue is not conserved in

Drosophila melanogaster, flies remain an important *in vivo* system for assessing variant

function. Hence, we generated transgenic flies that express AXIN2 reference (*AXIN2*^{REF}) or

variants under the control of an Upstream Activation Sequence (UAS). We generated the

p.E66K variant (*AXIN2*^{E66K}) present in three of the participants as well as two pathogenic

truncating variants (*AXIN2*^{R656X} and *AXIN2*^{W663X}) observed in oligodontia-colorectal cancer

syndrome (ODCRCS)[3,9]. All transgenes were inserted in the same genomic site in the flies,

controlling for positional effects, and ensuring similar protein expression levels (**Figure S6A**). In

parallel, we generated an *Axn*^{TG4} (*Axn*$^{T2A-GAL4}$) mutant *Drosophila* allele as part of a large-scale

resource[59]. As expected, this allele was homozygous lethal and remains lethal when *in trans*

with a corresponding deficiency line (*Df(3R)X3F*) lacking the *Axn* gene, indicating the *Axn*^{TG4}

mutant is loss-of-function. The *Axn*^{TG4} allele expresses a GAL4 transcriptional activator in the

same spatial and temporal pattern as the *Drosophila* gene, *Axn*. We found that expressing

human *AXIN2*^{REF} in heterozygous *Axn*^{TG4} flies (*Axn*$^{TG4/+}$ > *UAS- AXIN2*^{REF}/+) led to no adult flies

at 18°C and 22°C. These data suggested that *Axn*/*AXIN2* is likely dosage-sensitive in flies

which prevented us from conducting humanization-based rescue studies.

As an alternative to humanization, we turned to an overexpression-based strategy for assessing

the impact of reference versus variant human cDNA expression in flies in a tissue-specific

manner[75]. Given that AXIN2 has a known role in β-catenin-dependent Wnt signaling[17], we opted

to overexpress *AXIN2^{REF}* and variants in the developing wing of the fly using *nubbin-GAL4*[76]

where Wnt (wingless in flies) signaling is well characterized. The expression of *AXIN2^{REF}*

caused wing margin loss marked by posterior serration and bristle loss (**Figure 5A**). This

phenotype was enhanced by increasing the temperature as GAL4-mediated UAS expression of

the transgene is positively correlated with temperature[77] (**Figure 5A**; **Figure S6B**). Importantly,

overexpression of a GFP-tagged fly Axn (*Axn^{GFP}*)[18] causes a similar phenotype, albeit more

severe. These data indicate that Axn and AXIN2 exert similar effects in the developing wing

disc. In this context, the *AXIN2^{E66K}* variant leads to a consistently worse phenotype than

AXIN2^{REF} as demonstrated by smaller wings as well as the presence of ectopic bristles and

blisters (**Figure 5A**; **Figure S6B**). These data indicate that the p.E66K may act as a gain-of-

function with potential neomorphic functions. The *AXIN2^{R656X}* and *AXIN2^{W663X}* variants observed

in ODCRCS caused an even stronger phenotype than both *AXIN2^{REF}* or *AXIN2^{E66K}* as wings

were smaller with more pronounced wing margin loss across temperatures. These data indicate

that the ODCRCS variants may also act as a gain-of-function.

To confirm that *AXIN2* overexpression impacts wingless and that downstream canonical

signaling (Wnt/β-catenin signaling) is affected at the cellular level, we examined the developing

wing disc in third instar larvae. Compared to control wing discs expressing lacZ, the expression

of *AXIN2^{REF}* caused a decrease in Cut staining, a Wingless downstream effector (**Figure 5B**).

This diminished Cut expression is further reduced when the *AXIN2^{E66K}* or the ODCRCS variants

are overexpressed in the developing wing disc, but only statistically significant with the

ODCRCS variants suggesting an intermediate function of the p.E66K variant (**Figure 5C**). In

line with this, the expression of Sens, a wingless responsive transcription factor expressed

adjacent to wingless secreting cells of the dorsal-ventral boundary is decreased in a similar

fashion (**Figure S7A**). Sens expression is almost completely absent when either the $AXIN2^{E66K}$

or the ODCRCS variants are overexpressed in the developing wing disc (**Figure 5D**).

Intriguingly, the Wingless ligand is also diminished in $AXIN2^{REF}$, $AXIN2^{E66K}$ and the ODCRCS

variants to similar degrees (**Figure 5E and Figure S7B).** These data indicate that both the

p.E66K and truncations observed in ODCRCS inhibit wingless signaling (WNT signaling) in this

tissue and can act as gain-of-function variants in this context.

To examine the impact of *AXIN2* variants in another cell context, we chose to overexpress

AXIN2 in the developing *Drosophila* eye using *ey-GAL4*. Although typically a dispensable tissue

in flies, expression with *ey-GAL4* can sometimes lead to lethality. Here, overexpression of fly

Axn^{GFP} with *ey-GAL4* causes 100% pupal lethality at 22°C. Overexpression of $AXIN2^{REF}$ or

$AXIN2^{E66K}$ causes ~75% and ~50% pupal lethality, respectively (**Figure 6A**). In surviving

progeny, flies expressing $AXIN2^{REF}$ display a smaller eye compared to $AXIN2^{E66K}$ (**Figure 6B-C**).

These data suggest that when expressed in the fly eye, the p.E66K acts as a loss-of-function.

On the contrary, the $AXIN2^{R656X}$ and $AXIN2^{W663X}$ variants observed in ODCRCS cause almost

~100% pupal lethality with the few survivors displaying extremely small eyes (**Figure 6C**).

Hence, like their function in the wing, the truncations observed in ODCRCS consistently display

gain-of-function activity.

Discussion

In this study, we identified four individuals who had previously unreported germline variants

(p.E66K and p.G67R) in the TNKS-binding domain of *AXIN2* and a phenotype that only partially

overlaps with ODCRCS, the only known Mendelian disorder associated with heterozygous

pathogenic variants in this gene[1-4,9,15,16]. Published phenotypes associated with germline *AXIN2*

variants include sparse hair and eyebrows, colonic polyps/polyposis, colorectal cancer, and

oligodontia or tooth agenesis[1-4,9,15,16,34]. Two recent publications suggested that cleft lip/palate,

olfactory neuroblastoma, and gastric adenoma should be included in the spectrum of germline

AXIN2-associated phenotypes[78,79]. In addition to several common ODCRCS phenotypes, the

patients in our cohort share several other overlapping phenotypes that include developmental

delays, microcephaly, digit and limb anomalies, ophthalmologic complications, genitourinary

anomalies, and unique facial features. Thus, the phenotypes caused by p.E66K and p.G67R

variants in *AXIN2* expand the phenotypic spectrum of AXIN2-related disorders. Pathogenic

variants in *AXIN2* associated with ODCRCS have been reported to impact multiple domains

except for the TNKS-binding domain[1-4,9,15,16,34,78]. To our knowledge, these two variants

described here are the first *AXIN2* pathogenic variants that impact the TNKS-binding domain.

Relative to ODCRCS, the more severe phenotypes of our patients with p.E66K or p.G67R

variants suggest the variants in the TNKS-binding domain of AXIN2 have a unique impact on

AXIN2 function. TNKS poly-ADP-ribosylates AXIN2, which leads to the ubiquitination and

proteasomal degradation of AXIN2[35,37]. Our structural modeling studies suggest that these

variants may directly impact TNKS binding to AXIN2. In particular, the p.G67R variant is

predicted to completely abolish AXIN2 binding to TNKS, while the p.E66K variant is predicted to

weaken the interaction with the main chain N-H of K362/S363 due to a less favorable charge

distribution, although a polar interaction with Serine 363 is still possible. In vitro studies of a

p.G74V mutation in AXIN1 (which is equivalent to p.G67V in AXIN2) demonstrated that this

mutation prevents TNKS from binding to AXIN1 in GST-pulldown assays, a finding that supports

our data[37]. Thus, a p.E66K or p.G67R variant may prevent TNKS and AXIN2 binding, which may

lead to increased stability of AXIN2.

The modeling of *de novo* heterozygous variants associated with severe early-onset phenotypes

is challenging in mice using traditional constitutive knock-in strategies due to expected lethality.

Thus, to circumvent this challenge, we used two mouse embryo screening approaches to

confirm the pathogenicity and phenotypes of the p.E66K variant, which was identified in 3 of the

4 participants in our cohort. Using both a CRISPR founder embryo screen and an innovative

prime editing N1 embryo screen, the p.E66K variant was found to cause shortened soft palate,

kinked tail, and digit abnormalities, phenotypes resembling the palate and skeletal abnormalities

observed in the participants. Moreover, the observed perinatal lethality of N1 mice heterozygous

for the p.E66K variant further supported pathogenicity. Given that the soft palate elevates during

swallowing to prevent food and fluids from going into the nasopharynx, we propose that p.E66K

heterozygous pups die shortly after birth due to nasal regurgitation. Importantly, the phenotypes

observed in mouse embryos heterozygous for the p.E66K variant contrast with the those in

published reports describing *Axin2* homozygous knockout mice, which are viable, fertile, and

have abnormal cranial suture closure[13,80-82]. This suggests that the effect of the p.E66K variant

on AXIN2 function is not simply loss-of-function.

Our fly modeling supports a complex and cell context-dependent effect of the p.E66K mutation

on AXIN2 function. Overexpression of the p.E66K and ODCRCS variant alleles caused more

severe phenotypes than overexpression of reference AXIN2 in the fly wing, indicating gain-of-

function for all variants tested. Overexpression of the p.E66K variant in the developing fly wing

also caused ectopic bristles, which were not observed in reference or ODCRCS variant

expressing wings, indicating potential neomorphic activity. In contrast, overexpression of the

p.E66K variant in the developing *Drosophila* eye caused less severe phenotypes compared to

reference, which is consistent with AXIN2 loss-of-function. Critically, overexpression of the

ODCRCS variants in the eye produced phenotypes consistent with AXIN2 gain-of-function, like

their overexpression in the wing. Thus, the effect of the p.E66K variant on AXIN2 function is

complex, context-dependent, and different than the ODCRCS variants, revealing a potential

underlying mechanism for phenotypic expansion.

In vitro, many ODCRCS variants produce premature stop codons distributed throughout *AXIN2*,

but some of these mutant transcripts appear to escape nonsense-mediated decay[83].

Consequently, truncated AXIN2 protein is produced, retains AXIN2 function, and demonstrates

increased stability in some situations[83]. These molecular characteristics are consistent with the

gain-of-function phenotypes observed when these variants are overexpressed in both the fly

wing and eye. Why the p.E66K variant in the TNKS binding domain revealed differential, cell

context-specific effects on AXIN2 function (i.e., gain-of-function versus loss-of-function) in our fly

models remains to be resolved. Cell context-specific roles for TNKS in the regulation of AXIN2

protein levels could play a role.

The function of AXIN2 in canonical Wnt signaling is primarily considered to be inhibitory, as

AXIN2 is a critical component of the β-catenin destruction complex in the absence of Wnt

signaling. However, once Wnt signaling is active, AXIN2 binds to and plays an important role in

maintaining the phosphorylation of the Lrp5/6 receptors, effectively promoting Wnt signaling[29-32].

The phenotypes observed in our mouse and fly models support this dichotomous role for AXIN2

in canonical Wnt signaling, which may also be cell context-dependent. Canonical Wnt/β-catenin

signaling in cranial neural crest (CNC)-derived mesenchymal cells is essential for proper

development of the soft palate, and the shortened soft palate phenotype in p.E66K

heterozygous embryos is consistent with disruption of Wnt signaling in these cells[84,85]. On the

other hand, the kinked tail phenotype observed in p.E66K heterozygous embryos is consistent

with hyperactivation of Wnt signaling in the neural tube[86]. Interestingly, previous studies of

mouse embryos harboring an ENU-induced p.V26D mutation in the tankyrase binding domain of

Axin2 (*Axin2^canp^*, **Figure S3**) revealed similar cell context-dependent effects with inhibition of

Wnt signaling in many embryonic tissues but a gain of Wnt signaling in the primitive streak[36].

Similarly, the phenotypes caused by AXIN2 overexpressed in the *Drosophila* wing are consistent

with inhibition of Wnt signaling[61,87]; the phenotypes induced by AXIN2 overexpressed in the

Drosophila eye are suggestive of Wnt signaling activation as Wnt plays an inhibitory role in

Drosophila eye development[88].

Based on patient phenotypes and our animal modeling data, we propose that specific variants

impacting the TNKS-binding domain of AXIN2 are associated with phenotypic expansion and a

novel Mendelian disorder with an underlying complex molecular mechanism. Future studies will

explore the cell context-specific effects of TNKS-binding domain variants on AXIN2 stability,

AXIN2 function, and Wnt/β-catenin signaling. The modeling strategies used to demonstrate the

pathogenicity of this variant may be beneficial for the resolution of other *de novo* heterozygous

variants of uncertain significance associated with congenital anomalies in humans.

Declaration of Interests

The Department of Molecular and Human Genetics at Baylor College of Medicine receives

financial support from Baylor Genetics. Dr. Brendan Lee serves on the Board of Directors of

Baylor Genetics and chairs its Scientific Advisory Board but receives no personal income from

these positions. XH is an employee of and may hold stock in GeneDx, LLC.

Acknowledgements

We thank the patients and families for participating in this study. Clinical research reported in

this publication was supported in part by National Institutes of Health (NIH) U01HG007709 to BL

and U01NS134348 to BL and JR. The genome sequencing for participant 1 was done through

the UDN Clinical Sequencing Core supported by NIH U01HG007942. Use of the Baylor College

of Medicine Intellectual and Developmental Disabilities Research Center Clinical translational

core was supported by P50HD103555. Fly modeling was supported by NIH U54NS093793,

R24OD022005, and R24OD031447 to HJB, OK and SY. Mouse modeling was supported by

NIH U54OD030165 to JDH and LCB. Use of the Macromolecular X-ray Crystallography Core at

Baylor College of Medicine was supported in part by NIH S10OD030246 to SL. Use of the

Optical Imaging & Vital Microscopy Core at the Baylor College of Medicine and the MicroCT

Imaging Facility at the McGovern Medical School at UTHealth was supported in part by NIH

S10OD030336. Use of the BCM Genetically Engineered Rodent Models Core was supported in

part by the Dan L. Duncan Comprehensive Cancer Center Support grant P30CA125123. The

content is solely the responsibility of the authors and does not necessarily represent the official

views of the National Institutes of Health. The mention of trade names, commercial products, or

organizations do not imply endorsement by the US Government. LCB and HTC are supported

by a Burroughs Wellcome Fund Career Award for Medical Scientists. HTC is supported by the

Cain Pediatric Neurology Research Foundation Laboratories and McNair Medical Institute at

The Robert and Janice McNair Foundation.

<u>Figure List</u>:

Figure 1. **Participant Phenotypes.** A) Pathogenic germline variants identified in *AXIN2*. The

variants we identified are shown in red, previously published variants associated with

oligodontia, oligodontia colorectal cancer syndrome, colon cancer and colon polyps previously

published are shown in black[1-4,15,16]. TNKS = Tankyrase binding domain, RGS = Regulator of G-

protein Signaling domain, GSK3β = Glycogen synthase kinase-3 beta binding domain, β-CAT =

Beta-catenin binding domain, DIX = Disheveled and AXIN (DIX) dimerization domain. B) *AXIN2*

missense allele counts derived from gnomAD aligned to human and mouse AXIN2 and AXIN1

amino acid alignments. Amino acids highlighted in red are conserved between all aligned

proteins, and positions 66 and 67 are highlighted in blue. The absence of variation in gnomAD

at positions 65 through 67 suggests that these residues may be critical for proper function of

AXIN2. Conservation alignment was created using default parameters in Clustal Omega[43].

Amino acids 60-75 from AXIN2 are shown, and amino acids 67-82 from AXIN1 are shown.

Variant allele counts were compiled from gnomAD_v4.0.0_ENSG00000168646_2.

Figure 2. **Structural Model of the AXIN2 variants.** A) ARC2 of TNKS is shown as a stick

model and surface representation. View looking from inside of the molecule toward the surface.

B) Bound TBM2 of AXIN2 is shown in stick and surface representation and is colored in green.

C) Bound TBM2 of the AXIN2 variant is shown in magenta. Enlarged view of the p.G67R mutant

showing steric clashes with surrounding residues. D) The Glu66 side chain of AXIN2 TBM2

(green) participates in an extensive hydrogen bond network (dotted red line) that stabilizes

complex formation. This hydrogen bond network would be disrupted by p.E66K mutation

(yellow). Water molecules are shown in red balls. The model was generated based on the

crystal structure of AXIN1 bound to TNKS (PDB ID: 3UTM).

Figure 3. **Production, genotyping, and phenotyping of p.E66K founder embryos.** A)

Outline of the process for generating and screening CRISPR founder embryos. B-D) Internal

and external µCT images of embryos at E18.5 with respective Sanger sequence traces. B) A

representative wild type embryo from the founder screen. No external anomalies are present

(left images), and the soft palate is the expected length (right images). C) Embryo with 96%

p.E66K knock-in allele contribution. This embryo had a kinked tail (left images) and had a

shortened soft palate not extending to the epiglottis (right images). D) Embryo with 53% p.E66K

knock-in allele contribution. This embryo also has a kinked tail (left images) and a shortened

soft palate (right images). Bottom images are magnified views of the areas in red boxes on the

top images. Arrowhead indicates normal soft palate extending to the epiglottis. Arrows indicate

shortened soft palates.

Figure 4. Production, genotyping, and phenotyping of the p.E66K knock-in mouse model.

A) Outline of the mosaic founder production and N1 screen for the p.E66K knock-in allele

generated with prime editing. B) Genotype distribution of N1 E18.5 embryos and liveborn

animals generated from the p.E66K mosaic founder. There were no N1 *Axin2*$^{E66K/+}$ animals at

weaning age, whereas about 50% of the embryos at E18.5 were carriers (p < 0.0001, Fisher's

exact for genotype distribution across timepoints). C) A representative E18.5 wild type embryo

from the N1 screen. No external anomalies are present (left images), and the soft palate is the

expected length, extending to the epiglottis (right images). D) A representative E18.5 *Axin2*$^{E66K/+}$

embryo with missing forelimb 5th digit (left images) and edema and a shortened soft palate not

extending to the epiglottis (right images). Bottom images are magnified views of the areas in red

boxes on the top images. Dashed arrow indicates edema. Arrowhead indicates normal soft

palate extending to the epiglottis. Arrows indicate missing digit and shortened soft palate.

Figure 5. The p.E66K acts as a gain-of-function variant in the *Drosophila* wing. A)

Representative images of adult fly wings expressing UAS-cDNA using *nubbin-GAL4* at the

temperatures indicated. A minimum of 60 wings were examined from three independent

crosses. Phenotypes were nearly 100% penetrant. B) Representative immunostaining of the Cut

protein in the developing wing disc at 22°C upon UAS-cDNA overexpression with *nubbin-GAL4*.

Scale bar = 40 µm. C-E) Quantification of fluorescence signal for Cut, Sens, and Wingless (Wg)

proteins in the developing wing disc upon overexpression of UAS-cDNA using *nubbin-GAL4* at

22°C. Immunostaining images for Sens and Wg are provided in Figure S7. ANOVA followed by

Tukey's post hoc test. $*p<0.05$, $**p<0.01$, $***p<0.001$, $****p<0.0001$.

Figure 6. The p.E66K acts as a loss-of-function variant in the *Drosophila* eye. A)

Quantification of pupal lethality upon overexpression of UAS-cDNA with ey-GAL4 at 22°C.

ANOVA followed by Tukey's post hoc test. $****p<0.0001$. B) Range of eye phenotypes identified

upon overexpression of UAS-cDNA with *ey-GAL4* at 22°C in surviving adult flies. C)

Representative images of eye phenotypes upon overexpression of UAS-cDNA with *ey-GAL4* at

22°C in surviving adult flies.

<u>**Supplemental Material**</u>

 Supplemental Figures

Figure S1. Genome editing approaches for the p.E66K founder embryos. A) Genome

editing with a sense strand derived sgRNA and anti-sense strand derived ssODN. B) Genome

editing with a sense strand derived sgRNA and anti-sense strand derived ssODN. Scissors

indicate sgRNA cut sites; asterisks indicate p.E66K mutation and p.G67 synonymous mutation.

The location of primers (E2 F and E2 R) used for PCR genotyping and Sanger sequencing are

shown.

Figure S2. Production and characterization of *Axin2$^{E66K/+}$* mosaic founder and N1

embryos. A) Prime editing production of a mosaic founder. Orange scissors indicate the

pegRNA; green scissors indicate the sgRNA for DNA nicking. The asterisk indicates p.E66K

mutation and p.G67 synonymous mutation. Insertion of the p.E66K mutation generates a StyI

restriction endonuclease cut site. The location of primers (E2 F and E2 R) used for PCR

genotyping and Sanger sequencing are shown. The 653 bp wild type PCR product is not

digested by StyI; the 653 bp p.E66K variant allele PCR products are digested by StyI, resulting

in 335 and 318 bp products. B) Sanger sequencing traces of the mosaic founder, a

representative Axin2$^{E66K/+}$ N1 embryo, and a representative wild type N1 embryo. The founder

male is mosaic for an allele harboring the p.E66K point mutation, a p.G67 synonymous

mutation, and a p.S70 (TCG>TCC) synonymous mutation. Co-transmission of the variants to N1

offspring confirms linkage. C) Representative PCR-StyI restriction digest genotyping results for

N1 embryos. NTC = no template control.

Figure S3. **Extended gnomAD conservation figure and *AXIN2* conservation across**

multiple species. A) Conservation alignment between *Homo sapiens* AXIN2, *Drosophila*

melanogaster AXN, and AXIN2 from various organisms (see methods and materials for full list).

Amino acids highlighted in red are 90-100% identical in the alignment, orange is 80-89%

identical, yellow is 70-79% identical. Positions 66 and 67 in human AXIN2 are highlighted in

blue, p.E66 and p.G67 are conserved in all organisms aligned except *D. melanogaster*. B)

AXIN2 missense allele counts derived from gnomAD aligned to *Homo sapiens* and *Mus*

musculus AXIN2, and *Homo sapiens* and *Mus musculus* AXIN1. Red color highlights amino

acids conserved between all aligned proteins, positions 66 and 67 are highlighted in blue. The

absence of variation in gnomAD at positions 65 through 67 suggests that these residues may be

critical for proper function of AXIN2. Missense variant allele counts were compiled from

gnomAD_v4.0.0_ENSG00000168646_2.

Figure S4. External imaging of embryos from the N1 screen. External μCT images of E18.5

wild type (WT, *Axin2*$^{+/+}$) and p.E66K heterozygous (Het, *Axin2*$^{E66K/+}$) embryos from the N1

screen. No external anomalies are present in wild type embryos; missing digit (N1-19) and

kinked tail phenotypes (N1-11, 15, 16, 22, 23) are observed in *Axin2*$^{E66K/+}$ embryos (arrows).

Figure S5. Internal imaging of embryos from the N1 screen. Internal, sagittal μCT images of

E18.5 wild type (*Axin2*$^{+/+}$) and p.E66K heterozygous (*Axin2*$^{E66K/+}$) embryos from the N1 screen.

No internal anomalies are present in wild type embryos, with the soft palate extending to the

epiglottis (box); all *Axin2*$^{E66K/+}$ embryos have a shortened soft palate not extending to the

epiglottis (box).

Figure S6. The p.E66K variant is stable and acts as a gain-of-function variant in the

***Drosophila* wing.** A) Representative western blot showing expression of UAS-AXIN2 cDNA

constructs are stable and relatively similar in level. B) Representative images of adult fly wings

expressing UAS-cDNA using *nubbin-GAL4* at the temperatures indicated. A minimum of 60

wings were examined from three independent crosses. Phenotypes were nearly 100%

penetrant.

Figure S7. The p.E66K variant leads to increased inhibition of Wingless signaling. A-B)

Representative immunostaining of the Sens and Wg protein in the developing wing disc at 22°C

upon UAS-cDNA overexpression with *nubbin-GAL4*. Scale bar = 40 μm.

Supplemental Tables

Table S1 – Guides for *Axin2* founder screen by traditional CRISPR HDR.

Table S2 – T Guides for Axin2 mouse model production by prime editing.

Table S3 – Prime editing pegRNA sequences.

Table S4 – Primers used for site-directed mutagenesis of AXIN2 for fly modeling.

Table S5 – Results of the ICE analysis of Sanger sequencing reads from p.E66K founder embryos.

Member Lists

Members of the UDN and members of the BCM CPMM lists are provided in supplemental material.

772
773   **Web Resources**:
774
AlphaFold2 Multimer, https://github.com/sokrypton/ColabFold
AlphaFold3, https://alphafoldserver.com
CADD, https://cadd.gs.washington.edu/
Catalogue of Somatic Mutations in Cancer (COSMIC), https://cancer.sanger.ac.uk/cosmic
Clinvar, https://www.ncbi.nlm.nih.gov/clinvar/

Clustal Omega, http://www.clustal.org/
Codified Genomics, https://codifiedgenomics.com
Developmental Studies Hybridoma Bank, https://dshb.biology.uiowa.edu/
Gnomad, https://gnomad.broadinstitute.org/
OMIM, https://www.omim.org/
Mouse Genome Informatics (MGI), https://www.informatics.jax.org/
Pegfinder, http://pegfinder.sidichenlab.org
REVEL, https://sites.google.com/site/revelgenomics/
Wellcome Sanger Institute Genome Editing (WGE), https://wge.stemcell.sanger.ac.uk/
Synthego Inference of CRISPR Edits (ICE), https://ice.synthego.com/#/
790

References

1. Beard, C., Purvis, R., Winship, I.M., Macrae, F.A., and Buchanan, D.D. (2019).
Phenotypic confirmation of oligodontia, colorectal polyposis and cancer in a family
carrying an exon 7 nonsense variant in the AXIN2 gene. Familial Cancer *18*, 311-315.
10.1007/s10689-019-00120-0.
2. Jensen, J.M., Skakkebæk, A., Gaustadness, M., Sommerlund, M., Gjørup, H.,
Ljungmann, K., Lautrup, C.K., and Sunde, L. (2022). Familial colorectal cancer and tooth
agenesis caused by an AXIN2 variant: how do we detect families with rare cancer
predisposition syndromes? Familial Cancer *21*, 325-332. 10.1007/s10689-021-00280-y.
3. Lammi, L., Arte, S., Somer, M., Järvinen, H., Lahermo, P., Thesleff, I., Pirinen, S., and
Nieminen, P. (2004). Mutations in AXIN2 Cause Familial Tooth Agenesis
and Predispose to Colorectal Cancer. The American Journal of Human Genetics *74*,
1043-1050. 10.1086/386293.
4. Yue, H., Liang, J., Yang, K., Hua, B., and Bian, Z. (2016). Functional analysis of a novel
missense mutation in AXIN2 associated with non-syndromic tooth agenesis. European
Journal of Oral Sciences *124*, 228-233. https://doi.org/10.1111/eos.12273.
5. Arenas, E. (2014). Wnt signaling in midbrain dopaminergic neuron development and
regenerative medicine for Parkinson's disease. Journal of Molecular Cell Biology *6*, 42-
53. 10.1093/jmcb/mju001.
6. Jia, L., Piña-Crespo, J., and Li, Y. (2019). Restoring Wnt/β-catenin signaling is a
promising therapeutic strategy for Alzheimer's disease. Molecular Brain *12*, 104.
10.1186/s13041-019-0525-5.
7. Wang, Q., Huang, X., Su, Y., Yin, G., Wang, S., Yu, B., Li, H., Qi, J., Chen, H., Zeng, W.,
et al. (2022). Activation of Wnt/β-catenin pathway mitigates blood–brain barrier
dysfunction in Alzheimer's disease. Brain *145*, 4474-4488. 10.1093/brain/awac236.
8. Lancaster, M.A., Louie, C.M., Silhavy, J.L., Sintasath, L., DeCambre, M., Nigam, S.K.,
Willert, K., and Gleeson, J.G. (2009). Impaired Wnt–β-catenin signaling disrupts adult
renal homeostasis and leads to cystic kidney ciliopathy. Nature Medicine *15*, 1046-1054.
10.1038/nm.2010.
9. Marvin, M.L., Mazzoni, S.M., Herron, C.M., Edwards, S., Gruber, S.B., and Petty, E.M.
(2011). AXIN2-associated autosomal dominant ectodermal dysplasia and neoplastic
syndrome. American Journal of Medical Genetics Part A *155*, 898-902.
https://doi.org/10.1002/ajmg.a.33927.
10. Yook, J.I., Li, X.-Y., Ota, I., Hu, C., Kim, H.S., Kim, N.H., Cha, S.Y., Ryu, J.K., Choi, Y.J.,
Kim, J., et al. (2006). A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast
cancer cells. Nature Cell Biology *8*, 1398-1406. 10.1038/ncb1508.

11. Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., and Yin, G.
(2022). Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic
opportunities. Signal Transduction and Targeted Therapy *7*, 3. 10.1038/s41392-021-
00762-6.
12. Satoh, S., Daigo, Y., Furukawa, Y., Kato, T., Miwa, N., Nishiwaki, T., Kawasoe, T.,
Ishiguro, H., Fujita, M., Tokino, T., et al. (2000). AXIN1 mutations in hepatocellular
carcinomas, and growth suppression in cancer cells by virus-mediated transfer of
AXIN1. Nature Genetics *24*, 245-250. 10.1038/73448.
13. Lustig, B., Jerchow, B., Sachs, M., Weiler, S., Pietsch, T., Karsten, U., van de Wetering,
M., Clevers, H., Schlag, P.M., Birchmeier, W., and Behrens, J. (2002). Negative
Feedback Loop of Wnt Signaling through Upregulation of Conductin/Axin2 in Colorectal
and Liver Tumors. Molecular and Cellular Biology *22*, 1184-1193.
10.1128/MCB.22.4.1184-1193.2002.
14. Korinek, V., Barker, N., Morin, P.J., van Wichen, D., de Weger, R., Kinzler, K.W.,
Vogelstein, B., and Clevers, H. (1997). Constitutive Transcriptional Activation by a β-
Catenin-Tcf Complex in APC−/− Colon Carcinoma. Science *275*, 1784-1787.
10.1126/science.275.5307.1784.
15. Chan, J.M., Clendenning, M., Joseland, S., Georgeson, P., Mahmood, K., Walker, R.,
Como, J., Joo, J.E., Preston, S., Hutchinson, R.A., et al. (2022). Rare germline variants
in the AXIN2 gene in families with colonic polyposis and colorectal cancer. Familial
Cancer *21*, 399-413. 10.1007/s10689-021-00283-9.
16. Leclerc, J., Beaumont, M., Vibert, R., Pinson, S., Vermaut, C., Flament, C., Lovecchio,
T., Delattre, L., Demay, C., Coulet, F., et al. (2023). AXIN2 germline testing in a French
cohort validates pathogenic variants as a rare cause of predisposition to colorectal
polyposis and cancer. Genes, Chromosomes and Cancer *62*, 210-222.
https://doi.org/10.1002/gcc.23112.
17. Wu, Z.-Q., Brabletz, T., Fearon, E., Willis, A.L., Hu, C.Y., Li, X.-Y., and Weiss, S.J.
(2012). Canonical Wnt suppressor, Axin2, promotes colon carcinoma oncogenic activity.
Proceedings of the National Academy of Sciences *109*, 11312-11317.
10.1073/pnas.1203015109.
18. Cliffe, A., Hamada, F., and Bienz, M. (2003). A Role of Dishevelled in Relocating Axin to
the Plasma Membrane during Wingless Signaling. Current Biology *13*, 960-966.
10.1016/S0960-9822(03)00370-1.
19. Ikeda, S., Kishida, S., Yamamoto, H., Murai, H., Koyama, S., and Kikuchi, A. (1998).
Axin, a negative regulator of the Wnt signaling pathway, forms a complex with GSK-3β
and β-catenin and promotes GSK-3β-dependent phosphorylation of β-catenin. The
EMBO Journal *17*, 1371-1384-1384. https://doi.org/10.1093/emboj/17.5.1371.
20. Jho, E.-h., Zhang, T., Domon, C., Joo, C.-K., Freund, J.-N., and Costantini, F. (2002).
Wnt/β-Catenin/Tcf Signaling Induces the Transcription of Axin2, a Negative Regulator of
the Signaling Pathway. Molecular and Cellular Biology *22*, 1172-1183.
10.1128/MCB.22.4.1172-1183.2002.
21. Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., Wang,
J., Doble, B., Woodgett, J., et al. (2008). Initiation of Wnt signaling: control of Wnt
coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions.
Development *135*, 367-375. 10.1242/dev.013540.
22. Rubinfeld, B., Albert, I., Porfiri, E., Fiol, C., Munemitsu, S., and Polakis, P. (1996).
Binding of GSK3β to the APC-β-Catenin Complex and Regulation of Complex Assembly.
Science *272*, 1023-1026. 10.1126/science.272.5264.1023.
23. Orford, K., Crockett, C., Jensen, J.P., Weissman, A.M., and Byers, S.W. (1997). Serine
Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin*. Journal of
Biological Chemistry *272*, 24735-24738. https://doi.org/10.1074/jbc.272.40.24735.

24.   Hart, M., Concordet, J.P., Lassot, I., Albert, I., del los Santos, R., Durand, H., Perret, C.,
Rubinfeld, B., Margottin, F., Benarous, R., and Polakis, P. (1999). The F-box protein β-
TrCP associates with phosphorylated β-catenin and regulates its activity in the cell.
Current Biology *9*, 207-211. 10.1016/S0960-9822(99)80091-8.
25.   Aberle, H., Bauer, A., Stappert, J., Kispert, A., and Kemler, R. (1997). β-catenin is a
target for the ubiquitin-proteasome pathway. The EMBO journal *16*, 3797-3804.
10.1093/emboj/16.13.3797.
26.   Behrens, J., von Kries, J.P., Kühl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and
Birchmeier, W. (1996). Functional interaction of β-catenin with the transcription factor
LEF-1. Nature *382*, 638-642. 10.1038/382638a0.
27.   Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S.,
Korinek, V., Roose, J., Destrée, O., and Clevers, H. (1996). XTcf-3 Transcription Factor
Mediates β-catenin-Induced Axis Formation in Xenopus Embryos. Cell *86*, 391-399.
10.1016/S0092-8674(00)80112-9.
28.   Moshkovsky, A.R., and Kirschner, M.W. (2022). The nonredundant nature of the Axin2
regulatory network in the canonical Wnt signaling pathway. Proceedings of the National
Academy of Sciences *119*, e2108408119. 10.1073/pnas.2108408119.
29.   Zeng, X., Huang, H., Tamai, K., Zhang, X., Harada, Y., Yokota, C., Almeida, K., Wang,
J., Doble, B., Woodgett, J., et al. (2008). Initiation of Wnt signaling: control of Wnt
coreceptor Lrp6 phosphorylation/activation via frizzled, dishevelled and axin functions.
Development *135*, 367-375. 10.1242/dev.013540.
30.   Mao, J., Wang, J., Liu, B., Pan, W., Farr, G.H., 3rd, Flynn, C., Yuan, H., Takada, S.,
Kimelman, D., Li, L., and Wu, D. (2001). Low-density lipoprotein receptor-related protein-
5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol Cell *7*, 801-809.
10.1016/s1097-2765(01)00224-6.
31.   Zeng, X., Tamai, K., Doble, B., Li, S., Huang, H., Habas, R., Okamura, H., Woodgett, J.,
and He, X. (2005). A dual-kinase mechanism for Wnt co-receptor phosphorylation and
activation. Nature *438*, 873-877. 10.1038/nature04185.
32.   Bilic, J., Huang, Y.L., Davidson, G., Zimmermann, T., Cruciat, C.M., Bienz, M., and
Niehrs, C. (2007). Wnt induces LRP6 signalosomes and promotes dishevelled-
dependent LRP6 phosphorylation. Science *316*, 1619-1622. 10.1126/science.1137065.
33.   Liu, W., Dong, X., Mai, M., Seelan, R.S., Taniguchi, K., Krishnadath, K.K., Halling, K.C.,
Cunningham, J.M., Qian, C., Christensen, E., et al. (2000). Mutations in AXIN2 cause
colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling.
Nature Genetics *26*, 146-147. 10.1038/79859.
34.   Bergendal, B., Klar, J., Stecksén-Blicks, C., Norderyd, J., and Dahl, N. (2011). Isolated
oligodontia associated with mutations in EDARADD, AXIN2, MSX1, and PAX9 genes.
American Journal of Medical Genetics Part A *155*, 1616-1622.
https://doi.org/10.1002/ajmg.a.34045.
35.   Huang, S.-M.A., Mishina, Y.M., Liu, S., Cheung, A., Stegmeier, F., Michaud, G.A.,
Charlat, O., Wiellette, E., Zhang, Y., Wiessner, S., et al. (2009). Tankyrase inhibition
stabilizes axin and antagonizes Wnt signalling. Nature *461*, 614-620.
10.1038/nature08356.
36.   Qian, L., Mahaffey, J.P., Alcorn, H.L., and Anderson, K.V. (2011). Tissue-specific roles
of Axin2 in the inhibition and activation of Wnt signaling in the mouse embryo.
Proceedings of the National Academy of Sciences *108*, 8692-8697.
10.1073/pnas.1100328108.
37.   Morrone, S., Cheng, Z., Moon, R.T., Cong, F., and Xu, W. (2012). Crystal structure of a
Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate
recruitment. Proceedings of the National Academy of Sciences *109*, 1500-1505.
doi:10.1073/pnas.1116618109.

38.   Landrum, M.J., Lee, J.M., Riley, G.R., Jang, W., Rubinstein, W.S., Church, D.M., and
Maglott, D.R. (2014). ClinVar: public archive of relationships among sequence variation
and human phenotype. Nucleic Acids Research *42*, D980-D985. 10.1093/nar/gkt1113.
39.   Yang, Y., Muzny, D.M., Xia, F., Niu, Z., Person, R., Ding, Y., Ward, P., Braxton, A.,
Wang, M., Buhay, C., et al. (2014). Molecular findings among patients referred for
clinical whole-exome sequencing. JAMA *312*, 1870-1879. 10.1001/jama.2014.14601.
40.   Keehan, L., Jiang, M.M., Li, X., Marom, R., Dai, H., Murdock, D., Liu, P., Hunter, J.V.,
Heaney, J.D., Robak, L., et al. (2021). A novel de novo intronic variant in ITPR1 causes
Gillespie syndrome. Am J Med Genet A *185*, 2315-2324. 10.1002/ajmg.a.62232.
41.   Chen, S., Francioli, L.C., Goodrich, J.K., Collins, R.L., Kanai, M., Wang, Q., Alföldi, J.,
Watts, N.A., Vittal, C., Gauthier, L.D., et al. (2022). A genome-wide mutational constraint
map quantified from variation in 76,156 human genomes. bioRxiv,
2022.2003.2020.485034-482022.485003.485020.485034. 10.1101/2022.03.20.485034.
42.   Goujon, M., McWilliam, H., Li, W., Valentin, F., Squizzato, S., Paern, J., and Lopez, R.
(2010). A new bioinformatics analysis tools framework at EMBL–EBI. Nucleic Acids
Research *38*, W695-W699. 10.1093/nar/gkq313.
43.   Sievers, F., Wilm, A., Dineen, D., Gibson, T.J., Karplus, K., Li, W., Lopez, R., McWilliam,
H., Remmert, M., Söding, J., et al. (2011). Fast, scalable generation of high-quality
protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology
7, 539. https://doi.org/10.1038/msb.2011.75.
44.   Söding, J. (2005). Protein homology detection by HMM–HMM comparison.
Bioinformatics *21*, 951-960. 10.1093/bioinformatics/bti125.
45.   UniProt, C. (2023). UniProt: the Universal Protein Knowledgebase in 2023. Nucleic
Acids Res *51*, D523-D531. 10.1093/nar/gkac1052.
46.   Emsley, P., Lohkamp, B., Scott, W.G., and Cowtan, K. (2010). Features and
development of Coot. Acta Crystallogr D Biol Crystallogr *66*, 486-501.
10.1107/S0907444910007493.
47.   Hodgkins, A., Farne, A., Perera, S., Grego, T., Parry-Smith, D.J., Skarnes, W.C., and
Iyer, V. (2015). WGE: a CRISPR database for genome engineering. Bioinformatics *31*,
3078-3080. 10.1093/bioinformatics/btv308.
48.   Lanza, D.G., Mao, J., Lorenzo, I., Liao, L., Seavitt, J.R., Ljungberg, M.C., Simpson, E.M.,
DeMayo, F.J., and Heaney, J.D. (2024). An oocyte-specific Cas9-expressing mouse for
germline CRISPR/Cas9-mediated genome editing. Genesis *62*, e23589.
https://doi.org/10.1002/dvg.23589.
49.   Chow, R.D., Chen, J.S., Shen, J., and Chen, S. (2021). A web tool for the design of
prime-editing guide RNAs. Nat Biomed Eng *5*, 190-194. 10.1038/s41551-020-00622-8.
50.   Hai, L., Szwarc, M.M., Lanza, D.G., Heaney, J.D., and Lydon, J.P. (2019). Using
CRISPR/Cas9 engineering to generate a mouse with a conditional knockout allele for
the promyelocytic leukemia zinc finger transcription factor. Genesis *57*, e23281.
https://doi.org/10.1002/dvg.23281.
51.   Nakao, K., Nakagata, N., and Katsuki, M. (1997). Simple and Efficient Vitrification
Procedure for Cryopreservation of Mouse Embryos. Experimental Animals *46*, 231-234.
10.1538/expanim.46.231.
52.   Nakagata, N., and Takeo, T. (2019). Basic mouse reproductive techniques developed
and modified at the Center for Animal Resources and Development (CARD), Kumamoto
University. Experimental Animals *68*, 391-395. 10.1538/expanim.19-0070.
53.   Dickinson, M.E., Flenniken, A.M., Ji, X., Teboul, L., Wong, M.D., White, J.K., Meehan,
T.F., Weninger, W.J., Westerberg, H., Adissu, H., et al. (2016). High-throughput
discovery of novel developmental phenotypes. Nature *537*, 508-514.
10.1038/nature19356.

54.   Takeo, T., Hoshii, T., Kondo, Y., Toyodome, H., Arima, H., Yamamura, K.-i., Irie, T., and
Nakagata, N. (2008). Methyl-Beta-Cyclodextrin Improves Fertilizing Ability of C57BL/6
Mouse Sperm after Freezing and Thawing by Facilitating Cholesterol Efflux from the
Cells1. Biology of Reproduction *78*, 546-551. 10.1095/biolreprod.107.065359.
55.   Takeo, T., and Nakagata, N. (2011). Reduced Glutathione Enhances Fertility of
Frozen/Thawed C57BL/6 Mouse Sperm after Exposure to Methyl-Beta-Cyclodextrin1.
Biology of Reproduction *85*, 1066-1072. 10.1095/biolreprod.111.092536.
56.   Chung, H.L., Mao, X., Wang, H., Park, Y.J., Marcogliese, P.C., Rosenfeld, J.A., Burrage,
L.C., Liu, P., Murdock, D.R., Yamamoto, S., et al. (2020). De Novo Variants in CDK19
Are Associated with a Syndrome Involving Intellectual Disability and Epileptic
Encephalopathy. Am J Hum Genet *106*, 717-725. 10.1016/j.ajhg.2020.04.001.
57.   Bischof, J., Bjorklund, M., Furger, E., Schertel, C., Taipale, J., and Basler, K. (2013). A
versatile platform for creating a comprehensive UAS-ORFeome library in Drosophila.
Development *140*, 2434-2442. 10.1242/dev.088757.
58.   Venken, K.J., He, Y., Hoskins, R.A., and Bellen, H.J. (2006). P[acman]: a BAC
transgenic platform for targeted insertion of large DNA fragments in D. melanogaster.
Science *314*, 1747-1751. 10.1126/science.1134426.
59.   Kanca, O., Zirin, J., Hu, Y., Tepe, B., Dutta, D., Lin, W.W., Ma, L., Ge, M., Zuo, Z., Liu,
L.P., et al. (2022). An expanded toolkit for Drosophila gene tagging using synthesized
homology donor constructs for CRISPR-mediated homologous recombination. Elife *11*.
10.7554/eLife.76077.
60.   Marcogliese, P.C., Dutta, D., Ray, S.S., Dang, N.D.P., Zuo, Z., Wang, Y., Lu, D., Fazal,
F., Ravenscroft, T.A., Chung, H., et al. (2022). Loss of IRF2BPL impairs neuronal
maintenance through excess Wnt signaling. Sci Adv *8*, eabl5613.
10.1126/sciadv.abl5613.
61.   Nolo, R., Abbott, L.A., and Bellen, H.J. (2000). Senseless, a Zn finger transcription
factor, is necessary and sufficient for sensory organ development in Drosophila. Cell
102, 349-362. 10.1016/s0092-8674(00)00040-4.
62.   Rentzsch, P., Schubach, M., Shendure, J., and Kircher, M. (2021). CADD-Splice-
improving genome-wide variant effect prediction using deep learning-derived splice
scores. Genome Med *13*, 31. 10.1186/s13073-021-00835-9.
63.   Ioannidis, N.M., Rothstein, J.H., Pejaver, V., Middha, S., McDonnell, S.K., Baheti, S.,
Musolf, A., Li, Q., Holzinger, E., Karyadi, D., et al. (2016). REVEL: An Ensemble Method
for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet *99*, 877-
885. 10.1016/j.ajhg.2016.08.016.
64.   Cheng, J., Novati, G., Pan, J., Bycroft, C., Zemgulyte, A., Applebaum, T., Pritzel, A.,
Wong, L.H., Zielinski, M., Sargeant, T., et al. (2023). Accurate proteome-wide missense
variant effect prediction with AlphaMissense. Science *381*, eadg7492.
10.1126/science.adg7492.
65.   Morrone, S., Cheng, Z., Moon, R.T., Cong, F., and Xu, W. (2012). Crystal structure of a
Tankyrase-Axin complex and its implications for Axin turnover and Tankyrase substrate
recruitment. Proc Natl Acad Sci U S A *109*, 1500-1505. 10.1073/pnas.1116618109.
66.   Sondka, Z., Dhir, N.B., Carvalho-Silva, D., Jupe, S., Madhumita, McLaren, K., Starkey,
M., Ward, S., Wilding, J., Ahmed, M., et al. (2024). COSMIC: a curated database of
somatic variants and clinical data for cancer. Nucleic Acids Res *52*, D1210-D1217.
10.1093/nar/gkad986.
67.   Evans, R., O'Neill, M., Pritzel, A., Antropova, N., Senior, A., Green, T., Žídek, A., Bates,
R., Blackwell, S., Yim, J., et al. (2022). Protein complex prediction with AlphaFold-
Multimer. bioRxiv, 2021.2010.2004.463034. 10.1101/2021.10.04.463034.
68.   Abramson, J., Adler, J., Dunger, J., Evans, R., Green, T., Pritzel, A., Ronneberger, O.,
Willmore, L., Ballard, A.J., Bambrick, J., et al. (2024). Accurate structure prediction of

biomolecular interactions with AlphaFold 3. Nature *630*, 493-500. 10.1038/s41586-024-
07487-w.

69.   Guettler, S., LaRose, J., Petsalaki, E., Gish, G., Scotter, A., Pawson, T., Rottapel, R.,
and Sicheri, F. (2011). Structural Basis and Sequence Rules for Substrate Recognition
by Tankyrase Explain the Basis for Cherubism Disease. Cell *147*, 1340-1354.
10.1016/j.cell.2011.10.046.

70.   Teboul, L., Murray, S.A., and Nolan, P.M. (2017). Phenotyping first-generation genome
editing mutants: a new standard? Mamm Genome *28*, 377-382. 10.1007/s00335-017-
9711-x.

71.   Liu, Y., Li, X., He, S., Huang, S., Li, C., Chen, Y., Liu, Z., Huang, X., and Wang, X.
(2020). Efficient generation of mouse models with the prime editing system. Cell Discov
6, 27. 10.1038/s41421-020-0165-z.

72.   Adikusuma, F., Lushington, C., Arudkumar, J., Godahewa, G.I., Chey, Y.C.J., Gierus, L.,
Piltz, S., Geiger, A., Jain, Y., Reti, D., et al. (2021). Optimized nickase- and nuclease-
based prime editing in human and mouse cells. Nucleic Acids Res *49*, 10785-10795.
10.1093/nar/gkab792.

73.   Park, S.J., Jeong, T.Y., Shin, S.K., Yoon, D.E., Lim, S.Y., Kim, S.P., Choi, J., Lee, H.,
Hong, J.I., Ahn, J., et al. (2021). Targeted mutagenesis in mouse cells and embryos
using an enhanced prime editor. Genome Biol *22*, 170. 10.1186/s13059-021-02389-w.

74.   Gao, P., Lyu, Q., Ghanam, A.R., Lazzarotto, C.R., Newby, G.A., Zhang, W., Choi, M.,
Slivano, O.J., Holden, K., Walker, J.A., 2nd, et al. (2021). Prime editing in mice reveals
the essentiality of a single base in driving tissue-specific gene expression. Genome Biol
22, 83. 10.1186/s13059-021-02304-3.

75.   Her, Y., Pascual, D.M., Goldstone-Joubert, Z., and Marcogliese, P.C. (2024). Variant
functional assessment in Drosophila by overexpression: what can we learn? Genome
67, 158-167. 10.1139/gen-2023-0135.

76.   Swarup, S., and Verheyen, E.M. (2012). Wnt/Wingless signaling in Drosophila. Cold
Spring Harb Perspect Biol *4*. 10.1101/cshperspect.a007930.

77.   Nagarkar-Jaiswal, S., Lee, P.-T., Campbell, M.E., Chen, K., Anguiano-Zarate, S., Cantu
Gutierrez, M., Busby, T., Lin, W.-W., He, Y., Schulze, K.L., et al. (2015). A library of
MiMICs allows tagging of genes and reversible, spatial and temporal knockdown of
proteins in Drosophila. eLife *4*, e05338. 10.7554/eLife.05338.

78.   Roht, L., Hyldebrandt, H.K., Stormorken, A.T., Nordgarden, H., Sijmons, R.H., Bos, D.K.,
Riegert-Johnson, D., Mantia-Macklin, S., Ilves, P., Muru, K., et al. (2023). AXIN2-related
oligodontia-colorectal cancer syndrome with cleft palate as a possible new feature.
Molecular Genetics & Genomic Medicine *11*, e2157. https://doi.org/10.1002/mgg3.2157.

79.   Macklin- Mantia, S.K., Hines, S.L., Chaichana, K.L., Donaldson, A.M., Ko, S.L., Zhai, Q.,
Samadder, N.J., and Riegert-Johnson, D.L. (2020). Case report expanding the germline
AXIN2- related phenotype to include olfactory neuroblastoma and gastric adenoma.
BMC Medical Genetics *21*, 161. 10.1186/s12881-020-01103-0.

80.   Yu, H.-M.I., Jerchow, B., Sheu, T.-J., Liu, B., Costantini, F., Puzas, J.E., Birchmeier, W.,
and Hsu, W. (2005). The role of Axin2 in calvarial morphogenesis and craniosynostosis.
Development *132*, 1995-2005. 10.1242/dev.01786.

81.   Yan, Y., Tang, D., Chen, M., Huang, J., Xie, R., Jonason, J.H., Tan, X., Hou, W.,
Reynolds, D., Hsu, W., et al. (2009). Axin2 controls bone remodeling through the β-
catenin–BMP signaling pathway in adult mice. Journal of Cell Science *122*, 3566-3578.
10.1242/jcs.051904.

82.   de Roo, J.J.D., Breukel, C., Chhatta, A.R., Linssen, M.M., Vloemans, S.A., Salvatori, D.,
Mikkers, H.M.M., Verbeek, S.J., and Staal, F.J.T. (2017). Axin2-mTurquoise2: A novel
reporter mouse model for the detection of canonical Wnt signalling. Genesis *55*, e23068.
https://doi.org/10.1002/dvg.23068.

83. Mazzoni, S.M., Petty, E.M., Stoffel, E.M., and Fearon, E.R. (2015). An AXIN2 Mutant
Allele Associated With Predisposition to Colorectal Neoplasia Has Context-Dependent
Effects on AXIN2 Protein Function. Neoplasia *17*, 463-472.
https://doi.org/10.1016/j.neo.2015.04.006.
84. Janeckova, E., Feng, J., Guo, T., Han, X., Ghobadi, A., Araujo-Villalba, A., Rahman,
M.S., Ziaei, H., Ho, T.V., Pareek, S., et al. (2023). Canonical Wnt signaling regulates soft
palate development by mediating ciliary homeostasis. Development *150*.
10.1242/dev.201189.
85. Iwata, J., Suzuki, A., Yokota, T., Ho, T.V., Pelikan, R., Urata, M., Sanchez-Lara, P.A.,
and Chai, Y. (2014). TGFbeta regulates epithelial-mesenchymal interactions through
WNT signaling activity to control muscle development in the soft palate. Development
141, 909-917. 10.1242/dev.103093.
86. Maupin, K.A., Droscha, C.J., and Williams, B.O. (2013). A Comprehensive Overview of
Skeletal Phenotypes Associated with Alterations in Wnt/beta-catenin Signaling in
Humans and Mice. Bone Res *1*, 27-71. 10.4248/BR201301004.
87. Micchelli, C.A., Rulifson, E.J., and Blair, S.S. (1997). The function and regulation of cut
expression on the wing margin of Drosophila: Notch, Wingless and a dominant negative
role for Delta and Serrate. Development *124*, 1485-1495. 10.1242/dev.124.8.1485.
88. Legent, K., and Treisman, J.E. (2008). Wingless signaling in Drosophila eye
development. Methods Mol Biol *469*, 141-161. 10.1007/978-1-60327-469-2_12.

1101

A

B

AXIN2 Tankyrase binding domain missense variant distribution

Figure 1.

Figure 2.

A

Production

CRISPR/Cas9 pronuclear microinjections in C57BL/6J mouse zygotes

Transfer embryos into pseudopregnant females

Sanger sequencing and phenotyping of E18.5 F0s

B

F0-3 (100% wild-type)

5 mm

2 mm

2 mm

1 mm

G A G G G C G G G C C T C C
Glu66 Gly67 Arg68 Ala69 Ser70

C

F0-10 (96% p.E66K knock-in)

5 mm

2 mm

2 mm

1 mm

A A G G G C C G G G C C T C C
Lys66 Gly67 Arg68 Ala69 Ser70

D

F0-27 (53% p.E66K knock-in)

5 mm

2 mm

2 mm

1 mm

G A G G G G C G G G C C T C C
A C
Glu66 Gly67 Arg68 Ala69 Ser70
Lys66

Figure 3.

A

Production

Prime editing (PE) → F0s genotyped and Sanger sequenced → Mosaic male founder identified

N1 Screen

Axin2 p.E66K PE founder ✕ C57BL/6J females → Live birth genotyping and phenotyping

Axin2 p.E66K PE founder → IVF C57BL/6J oocytes → E18.5 genotyping and phenotyping

B

| Genotype | Timepoint | | p-value |
	E18.5 (n)	Postnatal (n)	
Axin2^{+/+}	15	30	<0.0001
Axin2^{E66K/+}	14	0	

C N1-6 (*Axin2*^{+/+})

D N1-19 (*Axin2*^{E66K/+})

Figure 4.

Figure 5.

Figure 6.